<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The combination of <z:chebi fb="0" ids="52717">bortezomib</z:chebi> and rituximab was evaluated in patients with mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e>), follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (FL) and <z:e sem="disease" ids="C0024419" disease_type="Neoplastic Process" abbrv="">Waldenström macroglobulinaemia</z:e> (WM), in a Phase I and later, a randomized Phase II study </plain></SENT>
<SENT sid="1" pm="."><plain>In the randomized study, 42 patients with recurrent/refractory disease received either: <z:chebi fb="0" ids="52717">bortezomib</z:chebi> 1·3 mg/m(2) on days 1, 4, 8 and 11 of a 3-week cycle with rituximab 375 mg/m(2) on day 1 (21 patients) or: <z:chebi fb="0" ids="52717">bortezomib</z:chebi> 1·6 mg/m(2) and rituximab on days 1, 8, 15 and 22 of a 5-week cycle (with rituximab being given only in cycles 1 and 4).Twenty-eight patients were withdrawn (toxicity 16, progression 7, and 'patient choice' 5) </plain></SENT>
<SENT sid="2" pm="."><plain>The main toxicities were neurological, gastro-intestinal and haematological </plain></SENT>
<SENT sid="3" pm="."><plain>The overall response rate was 28/42(67%) and by histology: <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MCL</z:e> 11/19, FL 8/15, and WM 9/10 </plain></SENT>
<SENT sid="4" pm="."><plain>Ten of 28 responding patients remained progression-free at 1-3·5 years </plain></SENT>
<SENT sid="5" pm="."><plain>Toxicity and efficacy were equivalent between the two groups </plain></SENT>
<SENT sid="6" pm="."><plain>The combination has significant toxicity but is effective, particularly in patients with WM </plain></SENT>
</text></document>